ODI Pharma AB
Stockholm Stock ExchangeTotal Valuation
ODI Pharma AB carries a market capitalization of 43.99M, placing it among publicly traded companies globally.
| Market Cap | 43.99M |
| Enterprise Value | N/A |
Share Statistics
ODI Pharma AB currently has 18.35M shares outstanding.
| Shares Outstanding | 18.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.27, and the price-to-book ratio stands at 91.55.
| PE Ratio | N/A |
| PS Ratio | 2.27 |
| PB Ratio | 91.55 |
| P/TBV Ratio | 37.50 |
| P/FCF Ratio | 90.42 |
| P/OCF Ratio | 90.42 |
Financial Position
ODI Pharma AB maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.20 |
| Quick Ratio | 0.48 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 0.55 |
Financial Efficiency
| Return on Equity (ROE) | -40.44 |
| Return on Assets (ROA) | -3.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 165.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 4,206.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
ODI Pharma AB's stock has gained approximately 42.85714% over the past 52 weeks. The 50-day moving average sits at 3.30, while the 200-day moving average is 2.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | 42.85714% |
| 50-Day Moving Average | 3.30 |
| 200-Day Moving Average | 2.92 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ODI Pharma AB generated 29.62M in revenue and converted that into -276,992.00 in net income, yielding earnings per share of -0.02. EBITDA reached 384,692.00, while operating income came in at 384,692.00.
| Revenue | 29.62M |
| Gross Profit | 8.57M |
| Operating Income | 384,692.00 |
| Pretax Income | -272,786.00 |
| Net Income | -276,992.00 |
| EBITDA | 384,692.00 |
| EBIT | 384,692.00 |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Total book value stands at 733,216.00, with working capital of 1.78M providing operational flexibility.
| Cash & Cash Equivalents | 4.19M |
| Total Debt | N/A |
| Net Debt | -4.19M |
| Equity (Book Value) | 733,216.00 |
| Book Value Per Share | 0.04 |
| Working Capital | 1.78M |
Cash Flow
ODI Pharma AB produced 742,339.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | 742,339.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | 742,339.00 |
| FCF Per Share | 0.04 |
Margins
ODI Pharma AB operates with a gross margin of 28.94, reflecting its pricing power and cost economics. The operating margin of 1.30 and net profit margin of -0.94 provide insight into operational efficiency.
| Gross Margin | 28.94 |
| Operating Margin | 1.30 |
| Pretax Margin | -0.92 |
| Profit Margin | -0.94 |
| EBITDA Margin | 1.30 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.98 |
| FCF Yield | 1.11 |
Scores
ODI Pharma AB posts an Altman Z-Score of 7.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.75 |